This page has been archived on the Web
Information identified as archived is provided for reference, research or recordkeeping purposes. It is not subject to the Government of Canada Web Standards and has not been altered or updated since it was archived. Please contact us to request a format other than those available.
Archived - Market withdrawal of Baycol (cerivastatin) - Bayer Inc.
- Starting date:
- August 8, 2001
- Posting date:
- August 8, 2001
- Type of communication:
- Dear Healthcare Professional Letter
- Source of recall:
- Health Canada
- Healthcare Professionals
- Identification number:
This is duplicated text of a letter from BAYER INC.
Contact the company for a copy of any references, attachments or enclosures.
Important Drug Safety Information
August 8, 2001
Dear Healthcare Professional:
I am writing to inform you of very important new safety information about Baycol (cerivastatin) and rhabdomyolysis.
Rhabdomyolysis is a serious, potentially fatal, adverse effect of all statin drugs, including Baycol. It can occur with statin monotherapy, though the risk appears to be increased significantly by concomitant use of gemfibrozil.
Our ongoing scrutiny of post-marketing reports of rhabdomyolysis, including fatalities, has revealed an increased reporting rate of rhabdomyolysis with Baycol relative to other statins, especially when gemfibrozil is co-prescribed. These data also suggest an increased reporting rate of rhambdomyolysis at the 0.8 mg dose of Baycol alone.
Bayer Inc. has already placed a contraindication in the Baycol Product Monograph against coprescription with gemfibrozil and communicated to healthcare professionals warning against coprescription of these two drugs. Despite these and other actions, Bayer has continued to receive reports of rhabdomyolysis when gemfibrozil is prescribed as a co-medication. Since the co-prescription of Baycol and gemfibrozil has continued despite communications by Bayer against this practice, the company has decided to take the following voluntary action to prevent further cases of rhabdomyolysis:
Effective immediately, Bayer has discontinued the marketing and distribution of all dosage strengths of Baycol. Patients who are currently taking Baycol should have their Baycol discontinued and be switched to an alternative therapy.
Bayer is taking this action as part of an ongoing commitment to patients and their healthcare providers to ensure patient safety.
It is important that you forward any adverse event information associated with the use of Baycol to Bayer Inc. at 1-800-265-7382. You can also report the information directly to Health Canada by fax at 613-957-0335.
If you have further questions regarding this action on Baycol, please contact Bayer Inc. at 1-800-265-7382.
original signed by
Neil S. Maresky, M.B., B.Ch.
Medical and Scientific Affairs
Any suspected adverse drug reactions can be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Bureau of Licensed Product Assessment
Therapeutic Products Directorate
Address Locator: 0201C2
OTTAWA, Ontario, K1A 1B9
Tel: (613) 957-0337 or Fax: (613) 957-0335
Toll free for consumers and health professionals:
Tel: 866 234-2345, Fax: 866 678-6789